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To assess the usefulness of circulating microRNAs (miRNAs) as non-invasive molecular biomarkers for
early prediction of preeclampsia, a differential miRNA profiling analysis was performed in first-trimester
pooled sera from 31 early preeclampsia patients, requiring delivery before 34 weeks of gestation, and 44
uncomplicated pregnancies using microfluidic arrays. Among a total of 754 miRNAs analyzed, the presence
of 63 miRNAs (8%) was consistently documented in the sera from preeclampsia and control samples.
Nevertheless, only 15 amplified miRNAs (2%) seemed to be differentially, although modestly, represented
(fold change range: 0.4–1.4). After stem loop RT-qPCR from individual samples, the statistical analysis
confirmed that none of the most consistent and differentially represented miRNAs (3 overrepresented and 4
underrepresented) were differentially abundant in serum from preeclamptic pregnancies compared with
serum from normal pregnancies. Therefore, maternal serum miRNA assessment at first-trimester of
pregnancy does not appear to have any predictive value for early preeclampsia.
P
reeclampsia, a pregnancy-related syndrome that complicates approximately 2–5% of pregnancies, is a major
cause of maternal and perinatal morbidity and mortality1. Nowadays, preeclampsia still lacks a safe and
effective therapy, as well as reliable, early means of diagnosis and prediction. An accurate prediction of
preeclampsia is a major challenge in contemporary obstetrics, and resources are now focalized in the first
trimester of pregnancy, where prophylactic strategies may help to reduce the incidence of this disorder2.
Preeclampsia has been named the ‘‘disease of theories’’3 since its precise origin remains elusive. Several
hypotheses (e.g., immunological, placental ischemia, inflammatory and genetic) have been described to explain
its pathogenesis, but still remains poorly understood.
MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs (19–25 nucleotides) that have
proved important post-transcription regulators of gene expression4. Through sequence-specific base pairing on
the 39 untranslated regions of the target mRNAs and inhibition of protein translation or stimulation of transcript
degradation, miRNAs have the capacity to influence both physiological and pathological processes involving cell
differentiation, proliferation/growth, apoptosis, angiogenesis and inflammation4–6. Recent studies have also
proposed a role for miRNAs in cell-to-cell communication7. Indeed, miRNAs have been detected in most
extracellular fluids, particularly in plasma/serum8,9. Moreover, these circulating miRNAs appear resistant to
endogenous ribonuclease activity and, therefore, very stable in these environments9. This is likely due to both
their intrinsic structural features and their presentation, either particulate when associated to membranous
vesicles such as apoptotic bodies or exosomes9,10, or soluble when complexed to RNA-binding proteins such as
Ago2, high-density lipoproteins, or nucleophosmin11–13. Consequently, circulating miRNAs have been recently
postulated as useful biomarkers for a variety of conditions such as cancer, cardiovascular disorders, and immune-
inflammatory diseases14.
Since placental and fetal development and vascular homeostasis are disturbed in preeclampsia, important
regulatory events such as epigenetic factors and miRNAs could in turn become deregulated in preeclampsia
pathogenesis. Several studies have evaluated the expression of miRNAs in placental tissues with both conven-
tional and microarray approaches, and they identified genes differentially expressed in the transcriptome of
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altered circulating miRNAs later in pregnancy that are associated
with preeclamptic risk using RT-qPCR20–22 or high-throughput tech-
nologies such as microarrays23,24 and next-generation sequencing
(NGS)25,26. For example, using microarray analysis Wu et al. evalu-
ated the expression of circulating miRNA from third-trimester pre-
eclamptic women and reported 13 miRNA up-regulated, and 2
down-regulated, as compared to normal pregnancies23. Further-
more, application of NGS technology to profile circulating miRNAs
in the serum of preeclampsia versus normal pregnant women has also
found 22 miRNAs dys-regulated. Among these, 3 of them had been
previously reported to be dys-regulated in the placentas of preeclamp-
sia pregnancies25. Nevertheless, none of the reported differentially
abundant miRNAs overlapped in both studies.
To the best of our knowledge, no study has evaluated the presence
of circulating miRNAs in the maternal serum at first-trimester of
pregnancy. In the present study, our aim was to explore the potential
of miRNAs as an early predictive, minimally invasive biomarker of
preeclampsia.
Results
Differential circulating miRNA profiling from first-trimester
preeclampsia and healthy pregnancies. We designed a two-stage
case-control study, including first-trimester sera from 31 cases of
early preeclampsia and 44 uncomplicated pregnancies (controls),
to determine whether maternal circulating miRNA profiling could
predict preeclampsia at an early stage of development (Fig. 1). Cases
and controls were similar regarding maternal age, nulliparity and
smoking status. Conversely, they differed significantly for first-
trimester MAP and UtA Doppler evaluation (p , 0.001) and for
perinatal outcome data, such as gestational age at delivery (p ,
0.001), mode of delivery (p , 0.001), and neonatal outcome (24
newborns in the preeclampsia group (77%) were SGA neonates,
and 4 of them (13%) died during the perinatal period). The main
features of the studied population, according to the study groups, are
summarized in Table 1.
To estimate whether there was difference in the generalizable first-
trimester serum miRNA signatures between preeclampsia and un-
complicated pregnancies, we employed three TaqMan OpenArray
Human miRNA Panels and a study population of 31 early pree-
clampsia cases and 44 controls. These were interrogated using pools
of the different serum samples as surrogate training samples. This
pooling approach would only detect circulating miRNAs present in
the majority of patients/subjects within the group, reducing variation
between individuals and enriching for miRNAs most likely to change
between cases and control groups. On the other hand, circulating
miRNAs present at low levels or in only a few individuals would not
be detected. Thus, the 31 cases of preeclampsia were randomly
divided in 4 pools and the 44 controls in 5 pools (60 ml/individual
serum sample) and the corresponding pre-amplified cDNAs were
dispensed in each of 3 nanofluidic arrays (OA) according to the
following distribution: OA1 interrogated 2 pools of cases (n 5 6/
each) and 1 pool of controls (n 5 12), OA2 interrogated 1 pool of
cases (n 5 11) and 2 pools of controls (n 5 6/each), and OA3
interrogated 1 pool of cases (n 5 8) and 2 pools of controls (n 5
10/each).
Among a total of 754 miRNAs analyzed, 63 could be correctly
amplified (Ct , 31) in all sample pools and therefore were present
in the sera from preeclampsia and control samples (Supplementary
Fig. S1 online). We obtained a relatively good correlation of Ct values
both between control pools and between sample pools, which rein-
force the consistency and reliability of our pooling approach
(Supplementary Fig. S2 online). Furthermore, using a rather conser-
vative selection criteria to assess differential circulating miRNA
abundance between preeclampsia and controls (fold change $ 1.3
Figure 1 | Schematic diagram of the workflow for differential first-trimester circulating miRNA quantification of preeclampsia versus uncomplicated
pregnancies. 754 miRNAs were screened (OpenArray), and 7 selected miRNAs were further validated (TaqMan RT-qPCR) in first-trimester sera
from 31 preeclampsia (PE) cases and 44 controls.
www.nature.com/scientificreports
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or # 0.7, and at least 3 of the 4 sample pools having the same
tendency –towards higher abundance or lower abundance- respect
to the control pools) we found 15 of them differentially represented
(roughly one third more abundant and two thirds less abundant,
compared to their corresponding control pool counterparts)
(Fig. 2a). However, the overall differences in relative miRNA abund-
ance between preeclampsia and controls were not statistically sig-
nificant (except for miR-127; p 5 0.041, although no miRNA passed
the false discovery rate (FDR) correction) and fairly modest, as the
fold changes ranked between 0.4 and 1.4.
Circulating miRNA abundance validation by real-time quan-
titative stem-loop RT-PCR analysis. According to the OpenArray
profiling outcome, we proceeded to validate 7 of the most differen-
tially abundant miRNAs: miR-192, -143 and -125b (overrepre-
sented), and miR-127, -942, -126# and -221 (underrepresented)
(Fig. 2b). Thus, these particular miRNAs were subsequently re-
analyzed in each of the individual case and control samples (valida-
tion set) using stem-loop RT-qPCR27. The tendencies among the 7
miRNAs analyzed were conserved between the OpenArray platform
and the RT-qPCR assays (Fig. 3 and Table 2). Moreover, their
differential levels obtained by RT-qPCR were comparable,
although somehow slighter than those found by Open Array analy-
sis (as an example, see Supplementary Fig. S3 online). Consequently,
no significant differences between preeclampsia and controls were
found regarding the first-trimester levels of the above circulating
miRNAs (Fig. 4). Furthermore, the only significant correlations
between the levels of the 7 circulating miRNAs and the clinical
parameters of the preeclampsia patients was a moderate negative
correlation between miRNA-942 and the mean arterial pressure
(MAP) (rs 5 20.418; p 5 0.019), and rather weak correlations
between miR-143 and the ethnicity (rbs 5 20.401; p 5 0.028), the
parity (rbs 5 0.385; p 5 0.036) and the mean uterine artery Doppler
pulsatility index (UtA PI) (rs 5 20.373; p 5 0.043) (Supplementary
Table S2 and Supplementary Fig. S4 online).
Discussion
The prediction of preeclampsia is one of the most important goals in
maternal-fetal medicine due to the lack of a specific therapy for this
severe disorder, which affects the mother and consequently the fetus,
often requiring premature delivery. A screening test that could
identify women early in pregnancy later developing preeclampsia
would allow not only to increase surveillance of those women at risk,
but also to identify those who would benefit from a prophylactic
treatment2. Indeed, it has been recently proposed that the use of
low-dose aspirin initiated at or before 16 weeks of gestation may
reduce by 89% the incidence of preterm preeclampsia (delivery ,
37 weeks)28.
A growing body of evidence suggests that there are two forms of
preeclampsia based on differences in placental insufficiency, clinical
manifestations, and also fetal involvement1,29–31. The early-onset
form, requiring delivery before 34 weeks of gestation, is the most
studied and the one for whom first-trimester screening tests are
achieving increased sensitivities32–34.
Nevertheless, owing to its heterogeneity, elusive pathophysiology,
and the lack of specific markers, preeclampsia is unlikely to be
detected early by a single predictive parameter with sufficient accu-
racy to be clinically useful. Therefore, current efforts intend combin-
ing maternal characteristics and both biophysical and biochemical
markers assessed in the first-trimester, into multivariate algorithms
so that the risk of preeclampsia can be estimated with performance
levels that could reach clinical utility32–34. The importance of biophys-
ical parameters, such as maternal blood pressure and uterine artery
Doppler, has already been demonstrated in several reports29,34.
Moreover, a huge amount of different biochemical markers have
been evaluated: products of fetal and placental origin, markers of
renal or endothelial damage, markers of oxidative stress, angiogenic
and anti-angiogenic factors among others35. However the evidence is
not yet consistent, and studies assessing new biomarkers are highly
encouraged to better clarify the complex pathogenesis of the disorder
and, consequently, the best way to predict it.
The sera contain stable cell-free miRNAs, small non-coding RNAs
with important regulatory roles in proliferation, apoptosis and cell-
cell communication, which can be identified and quantified, making
them the ideal biomarker candidates for non-invasive diagnostic/
prognostic purposes14. Moreover, aberrant miRNA expression has
been recently linked to pregnancy complications, such as preeclamp-
sia36. Thus, we aimed to assess the potential of circulating miRNAs as
sensitive and specific biomarkers for the early diagnosis of pree-
clampsia, either by themselves or in predictive models when com-
bined with other biometrical variables, such as sonographic markers,
into multivariate algorithms35,37. Nevertheless, this study suggests
that circulating miRNAs in maternal serum are not useful for the
early prediction of women at risk of preeclampsia. In fact, circulating
miRNA levels did not differ significantly in women who developed
early preeclampsia as compared with uncomplicated pregnancies
when assessed at first-trimester of pregnancy using the OpenArray
platform, a reliable high-throughput technology allowing profiling
all known miRNAs with power similar to microarray and precision/
specificity of qPCR. The OpenArray technology is based on high-
density array of nanoliter PCR assays, making possible to do up to
3,072 real-time PCRs at a single experiment38. In contrast, three high-
Table 1 | Main clinical characteristics of the study groups
Characteristics n Preeclampsia n Controls p-Value
Age (years) 31 32.6 6 6.6 44 32.3 6 5.6 0.822
Pre-pregnancy BMI (kg/m2) 31 24.5 6 4.4 44 22.8 6 3.2 0.060
Non-Caucasian ethnicity 31 15 (48.4%) 44 8 (18.2%) ,0.001
Nulliparity 31 18 (58.1%) 44 24 (54.5%) 0.474
Smoking status 31 2 (6.5%) 44 5 (11.4%) 0.384
MAP (mmHg); median (IQR)* 31 90 (79–98) 37 71 (69–77) ,0.001
Mean UtA PI; median (IQR)* 31 2.4 (1.8–2.9) 37 1.6 (1.0–2.4) ,0.001
GA at delivery (weeks) 31 31.4 6 2.5 44 37.5 6 6.3 ,0.001
Cesarean section 30 25 (80.6%) 42 7 (15.9%) ,0.001
Birthweight (g) 30 1374 6 512 42 3232 6 726 ,0.001
Stillbirth or neonatal death 31 4 (12.9%) 44 0 (0.0%) 0.026
SGA newborns 31 24 (77.4%) 44 4 (9.1%) ,0.001
BMI: Body mass index; MAP: Mean arterial pressure; IQR: Interquartile range; UtA PI: Uterine artery Doppler pulsatility index; GA: gestational age; SGA: Small for gestational age; Data are reported as a
mean 6 SD, or n (%); bold font: statistically significant results.
*Data recorded at first-trimester screening (11 1 0-13 1 6 weeks’ gestation).
www.nature.com/scientificreports
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throughput studies have also recently assessed the expression profiles
of circulating miRNAs in serum samples of pregnant women with
and without preeclampsia, and reported several miRNAs to be dys-
regulated in the serum/plasma of preeclampsia pregnancies23,25,26.
However, these reports were conducted using serum/plasma samples
from a more advanced stage of gestation (third-trimester). Moreover,
although Yang et al.25 and Li et al.26, belonging to the same research
group, established a proof-of-concept regarding the feasibility, com-
prehensiveness and sensitivity of the next generation sequencing
technology, the small number of samples analyzed in both studies
(study 1: control group, n 5 1; mild preeclampsia group, n 5 2;
severe preeclampsia group, n 5 2; study 2: control group, n 5 4;
mild preeclampsia group, n 5 4; severe preeclampsia group, n 5 4)
casts doubts about the overall reliability of their data for preeclamp-
sia diagnosis/prognosis. Alternatively, using a hybridization-based
microarray approach, Wu et al.23 reported that among 821 human
Figure 2 | Differential abundance profile of first-trimester serum miRNAs in preeclampsia and uncomplicated pregnancies by the OpenArray
platform. (a) volcano plot of nanofluidics data shows fold changes in miRNA abundance between preeclampsia patients and control pregnancies. The 7
miRNAs selected for further validation (3 overrepresented and 4 underrepresented) are highlighted. (b) Levels of the above-selected circulating miRNAs
in preeclampsia compared with the mean circulating miRNAs in uncomplicated pregnancies. Columns: preeclampsia serum sample pools. Baseline:
mean of 4 serum sample pools from normal control pregnancies.
www.nature.com/scientificreports
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miRNAs detected by microarray, only 15 differentially expressed
miRNAs of twofold changes or more (and merely two of them with
fold changes higher than 4) were identified in plasma of women with
severe preeclampsia. Therefore, these outcomes further support the
notion that in our study the lack of miRNA discriminatory power
during the early, preclinical phase of preeclampsia is not due to a
limited sensitivity of the miRNA analysis technologies employed, but
would appear an outcome of the own etiology of the disease. In fact,
the overt clinical symptoms of preeclampsia do not develop until
week 20 of gestation onward. Accordingly, our study suggests that
circulating miRNAs may be a relatively late event in preeclampsia
development. Although aberrant uterine vascular remodeling is a
hallmark of preeclampsia pathogenesis, leading to reduced placental
perfusion during early pregnancy, perhaps the degree of stress/
damage inflicted into trophoblasts and endothelial cells by an
enhanced inflammatory response due to environmental/maternal
characteristics, genetic predisposition and/or immunological mala-
daptation is still scarce to induce abnormal levels of circulating
miRNAs during the first-trimester of pregnancy. Thus, increased
placental dysfunction may stimulate the gradual release of placental
mediators (including miRNAs) into the maternal circulation, leading
to further widespread maternal vascular injury and enhanced differ-
ential circulating miRNA profiles only at more advanced stages of
gestation.
Interestingly, although the differential abundance of 7 circulating
miRNAs uncovered by OpenArray analysis and chosen by further
validation was fairly small between preeclampsia and uncomplicated
pregnancies, most of them are multipurpose miRNAs that have
been clearly implicated in angiogenesis (miR-125b, miR-143,
miR-942)39–41, inflammation (miR-126#, miR-127, miR-192, miR-
221)42–45, hypoxia/ischemia (miR-127)46, and cell migration/remod-
elling (miR-125b, miR-143, miR-127)47–49, and some of them have
been found altered in placentas from pre-eclamptic pregnancies
(miR-126#, miR-192)36. Two of these circulating miRNAs (miR-
221 and miR-125b) have been found differentially abundant in
late-screening preeclampsia samples through high-throughput
sequencing by oligo ligation detection (SOLiD)25,26 and microarray23
profiling studies. Moreover, we have found in preeclampsia patients
a negative correlation between miR-942 levels and the maternal
arterial pressure, and between miR-143 levels and the uterine artery
Doppler pulsatility index, in agreement to their recently reported
roles in the regulation of blood pressure and vascular function41,50,
which might be suggestive of usefulness as prognostic markers.
Indeed, altered angiogenic balance, systemic inflammation and pla-
cental hypoxia and ischemia, among others, contribute to the patho-
genesis of preeclampsia51.
However, we could not further confirm the differential abundance
of these 7 miRNAs in individual samples by TaqMan stem-loop RT-
qPCR, a prominent assay designed to detect and quantify mature
miRNAs in a fast, specific, accurate and reliable manner52.
For miRNA measurement, there are conflicting reports regarding
the reproducibility of different high-throughput profiling technolo-
gies53–55. Nevertheless, the results obtained in our study suggest cor-
relation, rather than lack of correlation, between both the OpenArray
and the TaqMan RT-qPCR techniques. Indeed, the tendency (toward
higher or lower abundancy) of the 7 miRNAs is the same comparing
the OpenArray system (performed with ‘‘pooled’’ samples) and the
TaqMan RT-pPCR system (performed with individual samples).
After all, the slight differences in differential fold changes between
both platforms could be due to minor variations in the cDNA pre-
amplification step from both technologies to enhance sensitivity, or
could be ascribed simply to the different normalization methods
employed (‘‘global mean normalization’’ in the OpenArray platform,
versus ‘‘spiked-in cel-miR-54 normalization’’ in the Taq-Man RT-
qPCR platform). In fact, a recent report analyzing maternal plasma
miRNA expression profiles in preeclamptic pregnancies compared
with normal pregnancies through sequencing by oligo ligation detec-
tion (SOLiD), identified 51 miRNAs differentially expressed, and 4 of
them were further validated by TaqMan RT-qPCR26. Thus, a com-
parison of the two platforms employed in the referred study (SOLiD
sequencing versus TaqMan RT-qPCR) revealed that the differential
abundance of these 4 validated miRNAs was significantly attenuated
in the TaqMan RT-qPCR platform respect to that obtained in the
SOLiD sequencing platform, analogously to that observed in our
study between the OpenArray and the TaqMan RT-qPCR platforms.
Among the limitations of the current analysis we acknowledge that
this was a nested case-control study including small numbers of
patients with preeclampsia. However, we believe it unlikely that
increasing the sample size would have resulted in remarkable differ-
ences in the results. In addition, we conducted the study in a low risk
Mediterranean population. We cannot yet exclude that studies in
other populations might yield different outcomes. Finally, in contrast
to the NGS technologies, the fixed number of miRNAs represented in
array-based platforms such as the high-throughput OpenArray sys-
tem might overlook non-represented (e.g., isomirs) or inconsistently
hybridized/amplified circulating miRNAs, although genuine differ-
entially abundant, influencing the outcome of the present study.
In summary, the development of a non-invasive, efficient screen-
ing procedure to identify women at risk of preeclampsia would be
beneficial for early-targeted preventive/prophylactic interventions.
Using miRNA microarray and real-time stem-loop RT-qPCR ana-
lyses, our study demonstrates that the maternally circulating miRNA
abundance profile in serum samples from early preeclampsia preg-
nancies is not significantly different in early gestation compared with
that from normal pregnancies. This suggests a minor predictive and
Figure 3 | Comparison of first-trimester serum miRNA abundance
between the OpenArray and the TaqMan RT-qPCR platforms. The
miRNAs analyzed are listed on the X-axis. The mean fold changes between
preeclampsia cases and healthy pregnancies are displayed in the Y-axis.
Gray bars represent OpenArray measurement results while solid bars
represent TaqMan measurements from the same miRNA (see Table 2).
Table 2 | Differential circulating miRNA levels in preeclampsia
compared to uncomplicated first-trimester pregnancies at both
the screening (OpenArray) and the validation (RT-qPCR) stages
miRNA FC (OpenArray) p-Value FC (RT-qPCR) p-Value
hsa-miR-126# 0.624 0.267 0.952 0.918
hsa-miR-127 0.437 0.041 0.720 0.404
hsa-miR-221 0.599 0.214 0.999 0.846
hsa-miR-942 0.467 0.322 0.896 0.530
hsa-miR-143 1.387 0.228 0.993 0.797
hsa-miR-125b 1.391 0.433 1.101 0.472
hsa-miR-192 1.407 0.208 1.043 0.749
FC, fold change.
www.nature.com/scientificreports
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functional pathophysiological relevance of circulating miRNAs dur-
ing the premature phase of the disease.
Methods
Study population. This nested case-control study was performed at the Department
of Maternal-Fetal Medicine (Hospital Clı́nic de Barcelona) and at the Molecular
Genetics Lab (IDIBELL). Maternal serum samples were obtained from a prospective
cohort composed of 5,759 unselected singleton pregnancies referring for routine first-
trimester screening for aneuploidies (11 1 0-13 1 6 weeks of gestation) between May
2009 and October 2011. Cases corresponded to women subsequently developing
preeclampsia and requiring delivery before 34 weeks of gestation (defined as early
preeclampsia). Controls were women referring in the same study period who had
normotensive pregnancies uncomplicated by proteinuria. The Clinical Research
Ethics Committee of the Hospital Clı́nic de Barcelona (CEIC Hospital Clı́nic)
approved the study protocol and each patient provided written informed consent.
Preeclampsia was defined as systolic blood pressure (BP) $ 140 mmHg and/or
diastolic BP $ 90 mmHg on at least two occasions 4 hours apart, developing after 20
weeks of gestation in a previously normotensive women, and proteinuria . 300 mg
in a 24-hour urine specimen56.
Exclusion criteria for both study groups were pregnancies with aneuploidies, major
fetal abnormalities, and those ending in termination, miscarriage or fetal death before
24 weeks of gestation. Gestational age in all pregnancies was calculated based on the
crown-rump length at first-trimester ultrasound57. Medical records were used to
obtain information on risk factors, pregnancy history, and perinatal outcome. Data
on maternal mean arterial pressure (MAP) and mean uterine artery (UtA) Doppler
pulsatility index (PI) measured at first-trimester screening were also recorded. Small
for gestational age (SGA) newborns were defined with birth weight below the 10th
centile according to local standards58. All experiments were carried out in accordance
with the approved guidelines and regulations, in line with the tenets of the
Declaration of Helsinki.
Sample collection and miRNA extraction. Thirty-one cases of early preeclampsia
and 44 controls were used in the study. The serum fractions were obtained according
to standard protocols. Briefly, the blood samples were collected in EDTA-containing
tubes, processed within one hour by centrifugation at 2,000 g for 10 min at 4uC, and
the supernatants were quickly removed, aliquoted, and stored immediately at 280uC.
For analysis, serum samples were thawed on ice and centrifuged at 3,000 g for 5 min,
avoiding the presence of traces of red blood cells and other cellular debris susceptible
to affect the microRNA profile. RNA was isolated from 200 ml of serum using the
miRNeasy Mini Kit (Qiagen, Venlo, The Netherlands), according to the
manufacturer’s protocol, and eluted with 50 ml of nuclease-free water.
miRNA Profiling on high-throughput OpenArrayTM system. The TaqManH
OpenArrayH Human MicroRNA Panel (Applied Biosystems, Foster City, CA, USA)
is a complete set of assays represented in Megaplex pools A and B. A total of 758
unique nanoliter PCR assays per sample, for 754 well-characterized human miRNAs
(Sanger miRBase v14) and 4 controls, are arranged on the OpenArray plate such that
3 samples can be interrogated on a single nanoplate. The assays are arranged so that
those from different pools are located in different subarrays with one replicate of each
control assay present in every subarray59.
MegaplexTM RT Primers, Human Pool A v2.1 and Human Pool B v3.0 (Applied
Biosystems) were used both for reverse transcription and for pre-amplification,
according to the manufacturer’s miRNA profiling workflow optimized for low sample
input. Briefly, reverse transcription (RT) (3 ml RNA/sample) was performed using the
TaqMan MicroRNA RT kit. The cDNA samples underwent unbiased PCR pre-
amplification using the TaqMan PreAmp Master Mix, and finally were PCR amp-
lified by incubation with the TaqMan OpenArray Real-Time PCR Master Mix onto
the through-hole nanofluidic OpenArray plate. The plates were processed in the UPF
Genomics Core Facility from Pompeu Fabra University (UPF, Barcelona).
OpenArray data analysis. OpenArray Real-Time qPCR Analysis Software (Applied
Biosystems) was used to analyze and review the amplification plots and threshold
cycle (Ct) values obtained. In some cases, manual adjustments to the baseline
parameters were made to individual assays. miRNA data analysis was performed with
DataAssistTM Software (Applied Biosystems) through global mean normalization of
all miRNAs that had Ct values lower than 31. The Benjamini-Hochberg procedure for
multiple testing correction was applied to calculate the False Discovery Rate (FDR)
for each of the p-values obtained.
Validation of OpenArray results. A fixed volume of 5 ml RNA per individual sample
was reverse transcribed using the TaqMan MicroRNA RT kit and 2 ml of miRNA-
specific stem-loop primers (Applied BioSystems) in a small-scale RT reaction
[comprised of 1.10 ml of nuclease-free water, 1 ml of 103 of RT Buffer, 0.13 ml of
Figure 4 | First-trimester circulating miRNAs in patients with preeclampsia versus uncomplicated pregnancies. Circulating levels of miR-192,
miR-125b, miR-143, miR-126#, miR-221, miR-942 and miR-127, selected according the OpenArray results outcome, obtained from first-trimester-
analyzed preeclampsia patients (PE; n 5 31) and healthy pregnancies (control; n 5 44) and measured by real-time quantitative stem-loop RT-PCR.
Serum miRNA levels were calculated by the 22DDCT method. The upper and lower limits of the boxes and the lines inside the boxes indicate the 75th and 25th
percentiles and the median, respectively. Upper and lower horizontal bars denote the 90th and 10th percentiles. The values are normalized to cel-miR-54
and shown as relative expression at y-axis. The first-trimester serum levels of all miRNAs analyzed were not significantly different between preeclampsia
and control groups.
www.nature.com/scientificreports
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RNase-Inhibitor (20 units/ml), 0.10 ml of 100 mM dNTPs and 0.67 ml of Multiscribe
Reverse Transcriptase], using a 9700 PCR thermocycler system (Applied
BioSystems). To enhance sensitivity, a 2.5 ml aliquot of undiluted RT product was
combined with 7.5 ml of pre-amplification solution [5 ml of TaqMan PreAmp Master
Mix and 2.5 ml of TaqMan miRNA Assay] and amplified in the 9700 PCR
thermocycler system (Applied Biosystems) by heating to 95uC for 10 min, followed
by 10 cycles of 95uC for 15 s and 60uC for 4 min.
Finally, 2.5 ml of diluted (155) pre-amplified product was combined with 5 ml of
TaqMan Universal PCR Master Mix with no AmpErase UNG (Applied Biosystems),
0.5 ml of TaqMan microRNA Assay 203 and 2 ml of nuclease-free water in a 10 ml
PCR reaction. Real-time PCR was carried out on an Applied BioSystems 7900 HT
thermocycler (50uC for 2 min and 95uC for 10 min, followed by 40 cycles of 95uC for
15 s and 60uC for 1 min). Data were analyzed with SDS RQ Manager 1.2.1 and
DataAssistTM Software (Applied BioSystems). The amplification curves were indi-
vidually inspected and miRNAs with abnormal amplification patterns were removed
from analysis. Normalization of sample-to-sample variation in RNA isolation was
approached including the synthetic C. elegans miRNA cel-miR-54 (Integrated DNA
Technologies, Coralville, IA, USA) to each denatured serum sample (after the addi-
tion of QIAzol Lysis Reagent in the initial RNA extraction procedure) to avoid its
degradation by endogenous serum RNases. The spiked-in cel-miR-54 (5 fmol) was
measured concomitantly to the miRNAs of interest. All reactions were run in trip-
licate. Data normalization across samples was performed using a median normal-
ization procedure. The Ct values were determined using the fixed threshold settings.
For each sample, the relative abundance of target miRNAs were determined by the
equation 2-DCt, in which DCt 5 Ct sample 2 Ct cel-miR-54. DDCt was then calculated by
subtracting the DCt of controls from the DCt of cases. The fold change in miRNA
abundance was calculated with the equation 22DDCt. Detailed information regarding
the miRNAs employed in this study is provided in Supplementary Table S1 online.
Statistical analysis. Comparisons between the clinico-pathological parameters of
preeclampsia and control groups were carried out using one-way ANOVA for
numerical data and Chi-Square for categorical data. Comparisons between cases
versus controls in the validation step were analyzed using the Mann-Whitney U-test
for unpaired data. The relationships of the miRNAs with the preeclampsia patient
clinical characteristics were analyzed by Spearman’s rank correlation or by Point-
Biserial correlation, where appropriate. All data analyses were performed using the
SPSS software version 15.0 (SPSS 15.0, SPSS Inc., Chicago, IL, USA). All tests were
two-tailed and p , 0.05 was considered statistically significant.
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